JAMA Network
About The Study: In this phase 3 randomized clinical trial that included 1,736 participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab, an antibody designed to clear brain amyloid plaque, significantly slowed clinical progression at 76 weeks in those with low/medium tau and in the combined low/medium and high tau pathology population.
Authors: John R. Sims, M.D., of Eli Lilly and Company in Indianapolis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.13239)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
